Entelos, Inc. announced that the US Patent and Trademark Office has granted US Patent No. 7,853,406 entitled “Predictive Toxicology for Biological Systems” to the company. This method to identify a potential toxicity of a therapy in a biological system, modelling a plurality of biological processes of the biological system, further strengthens the Entelos PhysioLab platforms to more efficiently and predicatively assess toxicity.

“We are pleased to add this new patent to our extensive array of patents and technology. This patent is a key component in enabling us to use the PhysioLab platforms to predict and confirm pathways that lead to toxicity with therapeutic interventions,” stated Julie Thomas Goggin, president and CEO of Entelos. “Our biosimulation platforms, with their ability to conduct insightful 'what if' analyses, have already led to better decisions in R&D. This new diagnostic capability will further enable us to better inform the design of clinical trials, as well as to avoid the serious consequences of unanticipated toxicity, such as Drug Induced Liver Injury (DILI).”

DILI is the leading cause of liver failure in the United States and is also the single major adverse drug event that terminates drug development programs and results in regulatory actions leading to failed or stalled drug approvals, market withdrawals, usage restrictions, and warnings to physicians.

This newly patented method expands the way in which Entelos' PhysioLab platforms can be utilized in the area of toxicity. This, in turn, can have a significant impact on patient safety as well as on the efficiency with which clinical trials are designed and effective, safe new medicines enter the market.

Entelos, Inc. is a life sciences company applying next-generation predictive technologies across multiple markets in R&D, healthcare, and finances to dramatically lower the risk, time, and cost of product development.